Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
Therapies with genetically modified T cells that express chimeric antigen receptors (CARs)
specific for CD19 or B cell maturation antigen (BCMA) are approved to treat certain B cell …
specific for CD19 or B cell maturation antigen (BCMA) are approved to treat certain B cell …
Killing mechanisms of chimeric antigen receptor (CAR) T cells
Effective adoptive T cell therapy (ACT) comprises the killing of cancer cells through the
therapeutic use of transferred T cells. One of the main ACT approaches is chimeric antigen …
therapeutic use of transferred T cells. One of the main ACT approaches is chimeric antigen …
[HTML][HTML] Targeting immune cells for cancer therapy
SY Gun, SWL Lee, JL Sieow, SC Wong - Redox biology, 2019 - Elsevier
Recent years have seen a renaissance in the research linking inflammation and cancer with
immune cells playing a central role in smouldering inflammation in the tumor …
immune cells playing a central role in smouldering inflammation in the tumor …
Low-dose radiation conditioning enables CAR T cells to mitigate antigen escape
CD19 chimeric antigen receptors (CARs) have demonstrated great efficacy against a range
of B cell malignancies. However, antigen escape and more generally heterogeneous …
of B cell malignancies. However, antigen escape and more generally heterogeneous …
Eradication of neuroblastoma by T cells redirected with an optimized GD2-specific chimeric antigen receptor and interleukin-15
Purpose: A delay in encountering the cognate antigen while in the circulation, and the
suboptimal costimulation received at the tumor site are key reasons for the limited activity of …
suboptimal costimulation received at the tumor site are key reasons for the limited activity of …
T cell fitness and autologous CAR T cell therapy in haematologic malignancy
PH Mehta, S Fiorenza, RM Koldej… - Frontiers in …, 2021 - frontiersin.org
A range of emerging therapeutic approaches for the treatment of cancer aim to induce or
augment endogenous T cell responses. Chimeric antigen receptor (CAR) T cell therapy …
augment endogenous T cell responses. Chimeric antigen receptor (CAR) T cell therapy …
Overcoming intrinsic resistance of cancer cells to CAR T-cell killing
In the past few years, chimeric antigen receptor (CAR) T-cell therapy has emerged as a
promising treatment for cancers that failed standard treatments. Such therapies have already …
promising treatment for cancers that failed standard treatments. Such therapies have already …
5-Fluorouracil Suppresses Colon Tumor through Activating the p53-Fas Pathway to Sensitize Myeloid-Derived Suppressor Cells to FasL+ Cytotoxic T Lymphocyte …
Simple Summary 5-Fluorouracil (5-FU), in combination with various therapeutic agents, is
the main strategy for patients with high risk of stage 2, and advanced stages of, human …
the main strategy for patients with high risk of stage 2, and advanced stages of, human …
Current progress of chimeric antigen receptor (CAR) T versus CAR NK cell for immunotherapy of solid tumors
Equip** cancer-fighting immune cells with chimeric antigen receptor (CAR) has gained
immense attention for cancer treatment. CAR-engineered T cells (CAR T cells) are the first …
immense attention for cancer treatment. CAR-engineered T cells (CAR T cells) are the first …
Overcoming heterogeneity of antigen expression for effective CAR T cell targeting of cancers
S Kailayangiri, B Altvater, M Wiebel, S Jamitzky… - Cancers, 2020 - mdpi.com
Chimeric antigen receptor (CAR) gene-modified T cells (CAR T cells) can eradicate B cell
malignancies via recognition of surface-expressed B lineage antigens. Antigen escape …
malignancies via recognition of surface-expressed B lineage antigens. Antigen escape …